A number of explanations have been proposed for underutilization of services, including stigma (
1,
6,
7), lack of appointment accessibility and availability (
1,
6,
11), perceptions of self-reliance (
12), and distrust or negative perceptions of care (
6,
13–
16). Several recent studies among U.S. and Canadian veterans have suggested that negative attitudes toward mental health care may be more important in initially seeking treatment than stigma and other traditional barriers (
13–
16).
With this descriptive study, we offer new findings on the adequacy of PTSD treatment received by active duty service members after returning from combat deployment. The principal study aims were to determine the percentage of soldiers in need of PTSD treatment after returning from deployment and the percentage receiving an adequate number of treatment sessions according to a standard definition of minimally adequate care. A secondary aim was to explore reasons for dropping out of care, including negative attitudes toward mental health treatment.
Discussion
Fostering engagement and willingness to remain in mental health treatment is critical to ensure the provision of evidence-based treatment to service members and veterans. This study provided important new findings, based on both cohort and cross-sectional methods, on the willingness of active duty soldiers to engage in and continue with needed treatment after combat deployment and provides additional qualitative data on reasons for dropping out of care. Despite the very different data collection methods, the two study groups had similar demographic characteristics (
Table 1) and provided remarkably complementary findings on health care utilization and adequacy of treatment.
Among the large cohort of soldiers who completed the clinical PDHA process, 10% were referred for further mental health evaluation, and 75% of these had documentation in their electronic health records of following up with this referral. This 75% rate is significantly higher than has been reported previously (42% was reported in 2007 [
17]), suggesting that efforts to improve postdeployment screening have been successful. However, despite this finding, the overall treatment reach for those most in need is estimated to remain low. Of 2,230 soldiers who received a PTSD diagnosis within 90 days of the PDHA, most did not have an adequate opportunity for evidence-based care; 22% had only one mental health visit (the one in which the diagnosis was made), and 41% received minimally adequate care, defined as eight or more visits involving this diagnosis within the ensuing year. Furthermore, previous research has documented that many soldiers returning from deployment are not willing to disclose concerns during the initial clinical PDHA process (
22).
Data from the cross-sectional infantry sample complemented the cohort findings. Among the 229 soldiers who screened positive for PTSD under strict case criteria, only 106 (48%) reported receiving any mental health care, and 25 (24%) soldiers reported dropping out of care. Overall satisfaction with care was moderate, with nearly a third reporting dissatisfaction. Among the 95 infantry soldiers who met criteria for PTSD and accessed care with a mental health professional, the total number of visits reported was strikingly similar to the much larger PDHA cohort; 22% of these soldiers reported receiving only one visit, which was identical to the percentage in the cohort based on documented encounters; 52% met the study definition for minimally adequate care, compared with 41% in the cohort. The overall reach of treatment was very low. Of all 229 infantry soldiers who screened positive for PTSD, only 49 (17%) received treatment that would be considered adequate, with the remainder either not receiving any care or receiving an insufficient number of sessions.
The definition of minimally adequate mental health treatment used in this study was a composite of definitions from the literature, which have included the criterion of four or more pharmacotherapy encounters in any clinic over either a six-month (
10) or 12-month (
8,
23) period, eight or more psychotherapy encounters over six (
10) or 12 (
8,
23) months, or nine or more encounters (either psychotherapy or pharmacotherapy) in a PTSD-specific Veterans Health Administration (VHA) clinic over 12 months (
9). However, all of these definitions have to do with only a minimally acceptable dose of care, not treatment adequacy, especially with the chronicity and comorbidities associated with PTSD and changing standards of clinical practice (
24). These definitions are crude estimates of what should be considered a minimal number of sessions necessary for provision of evidence-based care. Nevertheless, they have produced comparable results in veteran studies, with estimates ranging from 30% to 33% (
8–
10).
PTSD psychotherapy modalities typically involve weekly treatment sessions spanning 12 weeks. Pharmacotherapy treatment usually involves a number of sessions in the initial higher risk period (for example, four to six visits over the first 12 weeks) to ensure appropriate titration of medication dose and monitoring for suicidal ideation (due to FDA black-box warnings); thereafter, follow-ups typically occur every one to three months. Contrary to assumptions used in some definitions of “minimally adequate treatment,” we found that individuals with PTSD who were prescribed medications reported a significantly greater number of encounters than those not prescribed medications; this may reflect greater disease severity or more intensive follow-up for medication management according to revised standards. Recovery from PTSD in both psychotherapy and pharmacotherapy randomized clinical trials can reach 70%−80% among individuals who complete treatment (which usually involves at least eight visits, even for pharmacotherapy trials). However, dropout plagues virtually every treatment trial, leading to average recovery rates in intent-to-treat analyses of only around 40% (
24,
25). Furthermore, the total number of encounters alone says nothing about the provision of evidence-based strategies, the quality of treatment, or whether the focus of visits was even related to the index diagnosis instead of other comorbid conditions. Thus it is unlikely that either four sessions in six months or eight in 12 months truly reflects an adequate opportunity to receive evidence-based care with either psychotherapy or pharmacotherapy. The actual percentage of patients who receive adequate evidence-based care is therefore unknown but is likely to be lower than the 30%−33% estimate in previous veteran studies or the 41%−52% estimate in this study of active duty personnel.
To add to the above concerns of low treatment reach, this study provides new data on the specific reasons soldiers report for dropping out of mental health care. It is possible that the survey did not identify all who dropped out of treatment. Soldiers who missed follow-up appointments but intended to eventually return to treatment may not have endorsed the question on dropping out of care. However, despite this limitation, the 24% dropout rate among soldiers who met criteria for PTSD was comparable to rates found in clinical trials and civilian studies (
24,
26,
27). The wide range and high number of responses endorsed by each participant was impressive, spanning a variety of domains.
Concerns most commonly reported by soldiers included feeling like they could take care of problems on their own, not having sufficient time with the professional, work interference, stigma, confidentiality concerns, and the belief that care was ineffective. Two-thirds of soldiers also expressed discomfort with the interpersonal interaction with the mental health professional, including the perception that the professional was not suitably caring, communicative, or competent; soldiers sometimes felt judged or misunderstood. These data add to studies of the predictors of initial treatment access that have shown that negative attitudes may be more important than stigma perceptions (
13–
16), including civilian data showing that an important predictor of dropping out of treatment is the belief that treatment will not be effective (
26).
Limitations of this study include the reliance on administrative data for the cohort and self-report data for the cross-sectional survey. However, the large sizes of both study groups, high survey response rate, and especially the consistency in findings between the cross-sectional surveys and longitudinal clinical records strongly support the methodology and conclusions. The study provides a unique integration of findings from different sources related to mental health care utilization, adequacy, and satisfaction, as well as soldiers’ perceptions of care. Although there are some unique aspects of treatment immediately after exposure to traumatic events in the war zone, by the time service members return home, access care, and receive a diagnosis of PTSD, the standard of treatment remains eight or more encounters (
24). This study did not address potential benefits of brief or stepped-care interventions, which are being studied in primary care settings and which leverage strategies, such as motivational interviewing, behavioral activation, care management, phone follow-up, initiation of antidepressants, and treatment of comorbid sleep disturbance (
28).
This study represents a call to action to develop and test interventions to improve perceptions of mental health care and treatment engagement and retention in military, VHA, and civilian treatment settings. Dropping out of care is clearly the most important predictor of treatment failure; therefore the most promising strategies to improve efficacy of evidence-based treatments will be those that address engagement, therapeutic rapport, and retention. Particular attention is needed to better understand the modifiable organizational, patient, and clinician factors and specific actions that clinicians and health care systems can take. Interventions related to organizational barriers include ensuring adequate appointment availability and duration at convenient times and locations, as well as peer-to-peer outreach. Strategies to address patients’ beliefs about treatment should consider perceptions of self-reliance (for example through motivational interviewing techniques) (
29–
31). Policies concerning confidentiality, especially for treatment of comorbid substance use disorders, remain an ongoing issue in the military (
32). Clinician factors that warrant close examination concern the skills and training needed to optimally foster patient-centered care.
In a comprehensive review, Swift and colleagues (
27) suggested six strategies to minimize client dropout in civilian psychotherapy settings. These strategies include providing information to clients about therapy duration and expected patterns of change, educating clients about the roles and behaviors of the therapist and client, incorporating the client’s preferences for treatment, strengthening the client’s early hopes for therapy, fostering the therapeutic alliance and sustaining rapport, and assessing and discussing treatment progress at intervals. Many of these principles are inherent in patient-centered care. Factors likely to be particularly important in military and veteran populations include the ability of the clinician to communicate in way that is sensitive to the military occupational context and providing as wide a range of treatment options as possible (
24,
25,
33). Establishing ongoing simple measures of patient feedback is likely to be helpful (
34). Military health care systems should reevaluate how mental health treatment programs are structured and marketed. Embedding mental health treatment within primary care settings and coordinating care between primary and specialty care are also important strategies (
35). It is particularly important to consider integrated stepped approaches that enhance engagement through brief low-intensity treatments in primary care settings before stepping up to a specialty setting (
28,
36,
37).